RxDoctor Payments Data

Kiersten Mullis, DO

Family Medicine · Yanceville, NCNPI 1639632391

Payments from drug & device makers

$1,069in general payments, 2019–2025

Across 54 payments — averaging $19.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$289
  • Teva Pharmaceuticals USA, Inc.$230
  • AbbVie$63
  • Otsuka America Pharmaceutical, Inc.$62
  • Baxter Healthcare$60
  • Novo Nordisk$54
  • plus $312 from 9 others

What the payments were for

  • Food & beverage$1,00994%
  • Other$606%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,069 in reported general payments places this provider in the 70th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$4,343
Medicare patients
129
Services billed
293

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin141$115,974
OzempicSemaglutide70$89,521
TrulicityDulaglutide20$49,335
MounjaroTirzepatide29$45,274
EliquisApixaban45$42,233
RybelsusSemaglutide20$29,833
MyrbetriqMirabegron40$27,269
VascepaIcosapent Ethyl29$15,365
Spiriva HandihalerTiotropium Bromide16$13,953
Incruse ElliptaUmeclidinium Bromide17$11,876
JanuviaSitagliptin Phosphate17$11,373
AbrysvoRsv Vacc, Pref A And Pref B/Pf37$11,069
ShingrixVaricella-Zoster Ge/As01b/Pf48$10,148
CreonLipase/Protease/Amylase12$9,441
SymbicortBudesonide/Formoterol Fumarate22$7,999

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$54$119,35390 claims
Lilly USA, LLCTrulicity, Mounjaro$40$94,60949 claims
PfizerEliquis, Abrysvo$22$53,30282 claims
AbbVieCreon$63$9,44112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Yanceville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →